Details of Xenobiotics-DME Interaction (XEOTIC)

General Information of Drug-Metabolizing Enzyme (DME ID: DME0002)
DME Name Aromatase (CYP19A1), Homo sapiens DME Info
UniProt ID
CP19A_HUMAN
EC Number    EC: 1.14.14.14     (Click to Show/Hide the Complete EC Tree)
Oxidoreductase
Oxygen paired donor oxidoreductase
Flavin/flavoprotein donor oxidoreductase
EC: 1.14.14.14
Lineage    Species: Homo sapiens     (Click to Show/Hide the Complete Species Lineage)
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Interactome
Interactions between Xenobiotics and DME (XEOTIC)
      Fungicide(s), Herbicide(s) or Insecticide(s)
                  Fungicide Click to Show/Hide the Full List of Xenobiotics:      11 Xenobiotics
                              2,4,6-trichlorophenol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00962   XEOTIC Info Gene Form mRNA
                                 Classification Fungicide
                                 DME Modulation 2,4,6-trichlorophenol inhibits the expression of DME CYP19A1 [1]
                              Benomyl Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00939   XEOTIC Info Gene Form Protein
                                 Classification Fungicide
                                 DME Modulation Benomyl induces the drug-metabolizing activity of DME CYP19A1 [2]
                              Enilconazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00944   XEOTIC Info Gene Form Protein
                                 Classification Fungicide
                                 DME Modulation Enilconazole inhibits the drug-metabolizing activity of DME CYP19A1 [3]
                              Fenarimol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00946   XEOTIC Info Gene Form Protein
                                 Classification Fungicide
                                 DME Modulation Fenarimol inhibits the drug-metabolizing activity of DME CYP19A1 [4]
                              Flusilazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00948   XEOTIC Info Gene Form Protein
                                 Classification Fungicide
                                 DME Modulation Flusilazole inhibits the drug-metabolizing activity of DME CYP19A1 [5]
                              Hexaconazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00952   XEOTIC Info Gene Form Protein
                                 Classification Fungicide
                                 DME Modulation Hexaconazole inhibits the drug-metabolizing activity of DME CYP19A1 [6]
                              Prochloraz Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00955   XEOTIC Info Gene Form mRNA
                                 Classification Fungicide
                                 DME Modulation Prochloraz inhibits the expression of DME CYP19A1 [7]
                              Tebuconazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00957   XEOTIC Info Gene Form Protein
                                 Classification Fungicide
                                 DME Modulation Tebuconazole inhibits the drug-metabolizing activity of DME CYP19A1 [8]
                              Triadimefon Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00958   XEOTIC Info Gene Form mRNA
                                 Classification Fungicide
                                 DME Modulation Triadimefon inhibits the expression of DME CYP19A1 [9]
                              Triphenyltin chloride Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00961   XEOTIC Info Gene Form mRNA
                                 Classification Fungicide
                                 DME Modulation Triphenyltin chloride up-regulates the expression of DME CYP19A1 [10]
                              Vinclozolin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00960   XEOTIC Info Gene Form mRNA
                                 Classification Fungicide
                                 DME Modulation Vinclozolin up-regulates the expression of DME CYP19A1 [11]
                  Herbicide Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              Atrazine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00969   XEOTIC Info Gene Form Protein
                                 Classification Herbicide
                                 DME Modulation Atrazine inhibits the drug-metabolizing activity of DME CYP19A1 [12]
                              Metolachlor Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00976   XEOTIC Info Gene Form mRNA
                                 Classification Herbicide
                                 DME Modulation Metolachlor up-regulates the expression of DME CYP19A1 [13]
                  Pesticide/Insecticide Click to Show/Hide the Full List of Xenobiotics:        9 Xenobiotics
                              Bifenthrin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01040   XEOTIC Info Gene Form mRNA
                                 Classification Pesticide/Insecticide
                                 DME Modulation Bifenthrin up-regulates the expression of DME CYP19A1 [14]
                              Chlordecone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01598   XEOTIC Info Gene Form Protein
                                 Classification Pesticide/Insecticide
                                 DME Modulation Chlordecone inhibits the drug-metabolizing activity of DME CYP19A1 [12]
                              Cypermethrin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01046   XEOTIC Info Gene Form Protein
                                 Classification Pesticide/Insecticide
                                 DME Modulation Cypermethrin induces the drug-metabolizing activity of DME CYP19A1 [4]
                              Dicofol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01601   XEOTIC Info Gene Form Protein
                                 Classification Pesticide/Insecticide
                                 DME Modulation Dicof DMEol inhibits the drug-metabolizing activity of DME CYP19A1 [15]
                              Dicrotophos Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01050   XEOTIC Info Gene Form mRNA
                                 Classification Pesticide/Insecticide
                                 DME Modulation Dicrotophos inhibits the expression of DME CYP19A1 [16]
                              Endosulfan Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01074   XEOTIC Info Gene Form Protein
                                 Classification Pesticide/Insecticide
                                 DME Modulation Endosulfan induces the drug-metabolizing activity of DME CYP19A1 [4]
                              Heptachlor Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01055   XEOTIC Info Gene Form Protein
                                 Classification Pesticide/Insecticide
                                 DME Modulation Heptachlor inhibits the drug-metabolizing activity of DME CYP19A1 [4]
                              Imidacloprid Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01602   XEOTIC Info Gene Form Protein
                                 Classification Pesticide/Insecticide
                                 DME Modulation Imidacloprid induces the drug-metabolizing activity of DME CYP19A1 [17]
                              Pirimicarb Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01067   XEOTIC Info Gene Form mRNA
                                 Classification Pesticide/Insecticide
                                 DME Modulation Pirimicarb up-regulates the expression of DME CYP19A1 [18], [19]
      Health or Environmental Toxicant(s)
                  Acute Toxic Substance Click to Show/Hide the Full List of Xenobiotics:        3 Xenobiotics
                              Cadmium Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01503   XEOTIC Info Gene Form mRNA
                                 Classification Acute Toxic Substance
                                 DME Modulation Cadmium inhibits the expression of DME CYP19A1 [20]
                              Cycloheximide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01268   XEOTIC Info Gene Form Protein
                                 Classification Acute Toxic Substance
                                 DME Modulation Cycloheximide inhibits the drug-metabolizing activity of DME CYP19A1 [21]
                              Enniatins Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01289   XEOTIC Info Gene Form mRNA
                                 Classification Acute Toxic Substance
                                 DME Modulation Enniatins up-regulates the expression of DME CYP19A1 [22]
                  Carcinogen Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              Benzo(a)pyrene Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00898   XEOTIC Info Gene Form mRNA
                                 Classification Carcinogen
                                 DME Modulation Benzo(a)pyrene up-regulates the expression of DME CYP19A1 [23]
                              Aflatoxin B1 Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00806   XEOTIC Info Gene Form Protein
                                 Classification Carcinogen-mycotoxin
                                 DME Modulation Aflatoxin B1 induces the drug-metabolizing activity of DME CYP19A1 [24]
                  Environmental Pollutant Click to Show/Hide the Full List of Xenobiotics:        6 Xenobiotics
                              2-bromophenol Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01121   XEOTIC Info Gene Form mRNA
                                 Classification Environmental Pollutant
                                 DME Modulation 2-bromophenol up-regulates the expression of DME CYP19A1 [25]
                              Dichlorodiphenyl dichloroethylene Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00768   XEOTIC Info Gene Form Protein
                                 Classification Environmental Pollutant
                                 DME Modulation Dichlorodiphenyl dichloroethylene inhibits the drug-metabolizing activity of DME CYP19A1 [12]
                              Glyphosate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01320   XEOTIC Info Gene Form Protein
                                 Classification Environmental Pollutant
                                 DME Modulation Glyphosate inhibits the drug-metabolizing activity of DME CYP19A1 [26], [27]
                              Oxadiazon Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01416   XEOTIC Info Gene Form mRNA
                                 Classification Environmental Pollutant
                                 DME Modulation Oxadiazon up-regulates the expression of DME CYP19A1 [28]
                              p,p'-Hydroxy-DDT Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01110   XEOTIC Info Gene Form Protein
                                 Classification Environmental Pollutant
                                 DME Modulation p,p'-Hydroxy-DDT inhibits the drug-metabolizing activity of DME CYP19A1 [29]
                              Tetrabromobisphenol A Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00926   XEOTIC Info Gene Form mRNA
                                 Classification Environmental Pollutant
                                 DME Modulation Tetrabromobisphenol A inhibits the expression of DME CYP19A1 [30]
                  Health Hazard/Toxicant Click to Show/Hide the Full List of Xenobiotics:        6 Xenobiotics
                              Butylbenzyl phthalate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00998   XEOTIC Info Gene Form Protein
                                 Classification Health and Environmental Toxicant
                                 DME Modulation Butylbenzyl phthalate inhibits the drug-metabolizing activity of DME CYP19A1 [31]
                              Chlordan Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01245   XEOTIC Info Gene Form Protein
                                 Classification Health and Environmental Toxicant
                                 DME Modulation Chlordan induces the drug-metabolizing activity of DME CYP19A1 [4]
                              Dibutyl phthalate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01275   XEOTIC Info Gene Form Protein
                                 Classification Health and Environmental Toxicant
                                 DME Modulation Dibutyl phthalate inhibits the drug-metabolizing activity of DME CYP19A1 [31]
                              Iprodione Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00851   XEOTIC Info Gene Form Protein
                                 Classification Health and Environmental Toxicant
                                 DME Modulation Iprodione induces the drug-metabolizing activity of DME CYP19A1 [32]
                              4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01145   XEOTIC Info Gene Form Protein
                                 Classification Health Hazard
                                 DME Modulation 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid induces the drug-metabolizing activity of DME CYP19A1 [4]
                              Diethylhexyl phthalate Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01004   XEOTIC Info Gene Form mRNA
                                 Classification Health Hazard
                                 DME Modulation Diethylhexyl phthalate up-regulates the expression of DME CYP19A1 [33]
                  Mycotoxin Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              Deoxynivalenol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01514   XEOTIC Info Gene Form mRNA
                                 Classification Mycotoxin
                                 DME Modulation Deoxynivalenol inhibits the expression of DME CYP19A1 [34]
                              HT-2 toxin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01515   XEOTIC Info Gene Form mRNA
                                 Classification Mycotoxin
                                 DME Modulation HT-2 toxin inhibits the expression of DME CYP19A1 [34]
      Natural Product(s), Extract(s) or Medicine(s)
                  Natural Mixture Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              Flavonoids Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00858   XEOTIC Info Gene Form Protein
                                 Classification Natural Mixture
                                 DME Modulation Flavonoids inhibits the drug-metabolizing activity of DME CYP19A1 [35]
                              Tobacco smoke pollution Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00821   XEOTIC Info Gene Form mRNA
                                 Classification Natural Mixture
                                 DME Modulation Tobacco smoke pollution inhibits the expression of DME CYP19A1 [36]
                  Natural Product Click to Show/Hide the Full List of Xenobiotics:        9 Xenobiotics
                              7-hydroxyflavanone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01175   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation 7-hydroxyflavanone inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 3.8 microM) [37], [38]
                              7-hydroxyflavone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01176   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation 7-hydroxyflavone inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.0305 microM) [39]
                              Alpha-naphthoflavone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01192   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Alpha-naphthof DMElavone inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.07 microM) [39]
                              Apigenin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01203   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Apigenin inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.9 microM) [39]
                              Biochanin A Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01222   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Biochanin A inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.0102 microM) [39]
                              Chrysin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00878   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Chrysin inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.001 microM) [39]
                              Flavone Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01304   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Flavone induces the drug-metabolizing activity of DME CYP19A1 [35]
                              Hesperetin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00856   XEOTIC Info Gene Form Protein
                                 Classification Natural Product
                                 DME Modulation Hesperetin inhibits the drug-metabolizing activity of DME CYP19A1 [40]
                              Oleuropein Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01414   XEOTIC Info Gene Form mRNA
                                 Classification Natural Product
                                 DME Modulation Oleuropein inhibits the expression of DME CYP19A1 [41]
                  Plant Extract Click to Show/Hide the Full List of Xenobiotics:        1 Xenobiotics
                              Ginkgo biloba extract Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01314   XEOTIC Info Gene Form Protein
                                 Classification Plant Extract
                                 DME Modulation Ginkgo biloba extract inhibits the expression of DME CYP19A1 and leads to decreasing the drug-metabolizing activity of this enzyme [42]
      Pharmaceutical Agent(s)
                  Approved/Marketed Drug Click to Show/Hide the Full List of Xenobiotics:      56 Xenobiotics
                              Acetaminophen Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00217   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Acetaminophen up-regulates the expression of DME CYP19A1 [43]
                              Alitretinoin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00167   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Alitretinoin up-regulates the expression of DME CYP19A1 [44]
                              Aminoglutethimide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00233   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Aminoglutethimide inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.0052 microM) [39]
                              Amlodipine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00338   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Amlodipine inhibits the drug-metabolizing activity of DME CYP19A1 [3]
                              Amoxicillin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00246   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Amoxicillin induces the drug-metabolizing activity of DME CYP19A1 [45]
                              Anastrozole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00006   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Anastrozole inhibits the drug-metabolizing activity of DME CYP19A1 in Human choriocarcinoma cell line (JEG-3) (IC50 = 0.0015 microM) [46]
                              Calcitriol Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00184   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Calcitriol induces the drug-metabolizing activity of DME CYP19A1 [47]
                              Carmustine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00012   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Carmustine inhibits the expression of DME CYP19A1 [48]
                              Celecoxib Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00013   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Celecoxib inhibits the drug-metabolizing activity of DME CYP19A1 [49]
                              Citalopram hydrobromide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00283   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Citalopram hydrobromide inhibits the drug-metabolizing activity of DME CYP19A1 [50]
                              Clotrimazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00017   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Clotrimazole inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.0018 microM) [39]
                              Copper Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00834   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Copper up-regulates the expression of DME CYP19A1 [51]
                              Copper sulfate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00117   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Copper sulfate inhibits the expression of DME CYP19A1 [52]
                              Cyclosporine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00241   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Cyclosporine inhibits the expression of DME CYP19A1 [53]
                              Dehydroepiandrosterone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00393   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Dehydroepiandrosterone inhibits the drug-metabolizing activity of DME CYP19A1 [54]
                              Dexamethasone Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00088   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Dexamethasone induces the drug-metabolizing activity of DME CYP19A1 [55], [47]
                              Dienogest Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00433   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Dienogest inhibits the drug-metabolizing activity of DME CYP19A1 [56]
                              Diethylstilbestrol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00166   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Diethylstilbestrol inhibits the drug-metabolizing activity of DME CYP19A1 [12]
                              Dinoprostone Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00260   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Dinoprostone induces the drug-metabolizing activity of DME CYP19A1 [57]
                              Docetaxel Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00153   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Docetaxel inhibits the expression of DME CYP19A1 [58]
                              Erlotinib hydrochloride Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00157   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Erlotinib hydrochloride inhibits the drug-metabolizing activity of DME CYP19A1 [3]
                              Estradiol Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00090   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Estradiol induces the drug-metabolizing activity of DME CYP19A1 [59]
                              Estrone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00091   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Estrone inhibits the drug-metabolizing activity of DME CYP19A1 (Ki = 2.5 microM) [60]
                              Ethosuximide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00033   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ethosuximide inhibits the drug-metabolizing activity of DME CYP19A1 [61]
                              Exemestane Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00130   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Exemestane inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.0425 microM) [62]
                              Fluoxetine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00358   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Fluoxetine inhibits the drug-metabolizing activity of DME CYP19A1 [50]
                              Fluvoxamine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00360   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Fluvoxamine inhibits the drug-metabolizing activity of DME CYP19A1 [50]
                              Fulvestrant Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00147   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Fulvestrant inhibits the drug-metabolizing activity of DME CYP19A1 [63], [64]
                              Ibuprofen Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00248   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ibuprof DMEen inhibits the drug-metabolizing activity of DME CYP19A1 [49]
                              Indomethacin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00047   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Indomethacin inhibits the drug-metabolizing activity of DME CYP19A1 [49]
                              Ketoconazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00251   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Ketoconazole inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.04 microM) [65]
                              Lamotrigine Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00051   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Lamotrigine inhibits the drug-metabolizing activity of DME CYP19A1 [61]
                              Leflunomide Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00053   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Leflunomide up-regulates the expression of DME CYP19A1 [66]
                              Letrozole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00054   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Letrozole inhibits the drug-metabolizing activity of DME CYP19A1 in Human choriocarcinoma cell line (JEG-3) (IC50 = 0.00089 microM) [67]
                              Levetiracetam Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00187   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Levetiracetam inhibits the expression of DME CYP19A1 [68]
                              Lindane Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00740   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Lindane inhibits the drug-metabolizing activity of DME CYP19A1 [69]
                              Methotrexate Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00366   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Methotrexate up-regulates the expression of DME CYP19A1 [70]
                              Miconazole nitrate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00308   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Miconazole nitrate inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.6 microM) [39]
                              Perflubron Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00104   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Perflubron up-regulates the expression of DME CYP19A1 [71]
                              Phenobarbital Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00410   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Phenobarbital inhibits the expression of DME CYP19A1 [72]
                              Piroxicam Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00204   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Piroxicam inhibits the drug-metabolizing activity of DME CYP19A1 [73]
                              Progesterone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00094   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Progesterone inhibits the expression of DME CYP19A1 [74]
                              Tamoxifen Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00383   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Tamoxifen up-regulates the expression of DME CYP19A1 and leads to increasing the drug-metabolizing activity of this enzyme [75]
                              Testolactone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00114   XEOTIC Info Gene Form Protein
                                 Classification Drug Approved by US FDA
                                 DME Modulation Testolactone inhibits the drug-metabolizing activity of DME CYP19A1 (Ki = 35 microM) [76]
                              Testosterone Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00095   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Testosterone up-regulates the expression of DME CYP19A1 [77]
                              Tretinoin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00253   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Tretinoin up-regulates the expression of DME CYP19A1 [78]
                              Trovafloxacin mesylate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00333   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Trovafloxacin mesylate inhibits the expression of DME CYP19A1 [79]
                              Valproic acid Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00029   XEOTIC Info Gene Form mRNA
                                 Classification Drug Approved by US FDA
                                 DME Modulation Valproic acid inhibits the expression of DME CYP19A1 [80]
                              Bezafibrate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00493   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Bezafibrate inhibits the drug-metabolizing activity of DME CYP19A1 [81]
                              Bifonazole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00464   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Bifonazole inhibits the drug-metabolizing activity of DME CYP19A1 [5], [82]
                              Daidzein Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00439   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Daidzein inhibits the drug-metabolizing activity of DME CYP19A1 in Chinese hamster ovary (CHO) cell (Ki = 100 microM) [83]
                              Diethyl phthalate Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01033   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Diethyl phthalate induces the drug-metabolizing activity of DME CYP19A1 [84]
                              Estriol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00457   XEOTIC Info Gene Form mRNA
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Estriol inhibits the expression of DME CYP19A1 [24]
                              Fadrozole Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00468   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Fadrozole inhibits the drug-metabolizing activity of DME CYP19A1 in Human breast adenocarcinoma cell line (MCF-7) (IC50 = 0.000004 microM) [85]
                              Melatonin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00505   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Melatonin inhibits the drug-metabolizing activity of DME CYP19A1 [86]
                              Methoxychlor Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00446   XEOTIC Info Gene Form mRNA
                                 Classification Drug Marketed but not Approved by US FDA
                                 DME Modulation Methoxychlor up-regulates the expression of DME CYP19A1 [87], [88]
                  Drug in Phase 3 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              Afimoxifene Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00610   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 3
                                 DME Modulation Afimoxifene up-regulates the expression of DME CYP19A1 [89]
                              Resveratrol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00568   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 3
                                 DME Modulation Resveratrol inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 25 microM) [90], [91]
                  Drug in Phase 2 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:        3 Xenobiotics
                              Bisphenol A Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01226   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Bisphenol A inhibits the drug-metabolizing activity of DME CYP19A1 [92]
                              Colforsin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00606   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Colforsin induces the drug-metabolizing activity of DME CYP19A1 [93]
                              Genistein Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00557   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 2
                                 DME Modulation Genistein inhibits the drug-metabolizing activity of DME CYP19A1 in Chinese hamster ovary (CHO) cell (Ki = 100 microM) [83]
                  Drug in Phase 1 Clinical Trial Click to Show/Hide the Full List of Xenobiotics:      12 Xenobiotics
                              Bakuchiol Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00658   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1/2
                                 DME Modulation Bakuchiol inhibits the drug-metabolizing activity of DME CYP19A1 [94]
                              Carbendazim Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00598   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Carbendazim induces the drug-metabolizing activity of DME CYP19A1 [2]
                              Cyclic AMP Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01267   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Cyclic AMP induces the drug-metabolizing activity of DME CYP19A1 [95]
                              Fingolimod hydrochloride Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00554   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Fingolimod hydrochloride inhibits the expression of DME CYP19A1 [96]
                              Flavanone Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00738   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Flavanone inhibits the drug-metabolizing activity of DME CYP19A1 [97]
                              Naringenin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00573   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Naringenin inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.0029 microM) [39]
                              NS-398 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00583   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation NS-398 inhibits the drug-metabolizing activity of DME CYP19A1 in Human breast cancer cell line (SkBr3) (IC50 = 0.68 microM) [98], [21]
                              Phenanthrene Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00574   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Phenanthrene up-regulates the expression of DME CYP19A1 [99]
                              Quercetin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00538   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Quercetin inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.012 microM) [39]
                              SC-58125 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00623   XEOTIC Info Gene Form Protein
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation SC-58125 inhibits the drug-metabolizing activity of DME CYP19A1 [49]
                              Sodium arsenite Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00632   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Sodium arsenite up-regulates the expression of DME CYP19A1 [100], [101]
                              Tetradecanoylphorbol acetate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00599   XEOTIC Info Gene Form mRNA
                                 Classification Highest Clinical Status: Phase 1
                                 DME Modulation Tetradecanoylphorbol acetate inhibits the expression of DME CYP19A1 [102], [103]
                  Preclinical/Patented Drug Click to Show/Hide the Full List of Xenobiotics:        4 Xenobiotics
                              LG-100268 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00694   XEOTIC Info Gene Form Protein
                                 Classification Drug in Preclinical Study
                                 DME Modulation LG-100268 inhibits the drug-metabolizing activity of DME CYP19A1 [104]
                              Rottlerin Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00711   XEOTIC Info Gene Form Protein
                                 Classification Drug in Preclinical Study
                                 DME Modulation Rottlerin inhibits the drug-metabolizing activity of DME CYP19A1 [105]
                              AM-580 Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00728   XEOTIC Info Gene Form mRNA
                                 Classification Patented Pharmaceutical Agent
                                 DME Modulation AM-580 up-regulates the expression of DME CYP19A1 [44]
                              SC-560 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01468   XEOTIC Info Gene Form Protein
                                 Classification Patented Pharmaceutical Agent
                                 DME Modulation SC-560 inhibits the drug-metabolizing activity of DME CYP19A1 [106]
                  Drug Marketed but Withdrawn from Market Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              Formestane Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00518   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but Withdrawn from Market
                                 DME Modulation Formestane inhibits the drug-metabolizing activity of DME CYP19A1 [29]
                              Nimesulide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00519   XEOTIC Info Gene Form Protein
                                 Classification Drug Marketed but Withdrawn from Market
                                 DME Modulation Nimesulide inhibits the drug-metabolizing activity of DME CYP19A1 in Human breast cancer cell line (SkBr3) (IC50 = 27 microM) [107]
                  Investigative Agent Click to Show/Hide the Full List of Xenobiotics:        6 Xenobiotics
                              Beta-naphthoflavone Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01220   XEOTIC Info Gene Form mRNA
                                 Classification Investigative Agent
                                 DME Modulation Beta-naphthoflavone up-regulates the expression of DME CYP19A1 [108]
                              Bisindolylmaleimide Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01225   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation Bisindolylmaleimide inhibits the drug-metabolizing activity of DME CYP19A1 [109]
                              Butylparaben Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00930   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation Butylparaben inhibits the drug-metabolizing activity of DME CYP19A1 [110]
                              Mono-(2-ethylhexyl)phthalate Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO01380   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation Mono-(2-ethylhexyl)phthalate inhibits the drug-metabolizing activity of DME CYP19A1 [111], [112]
                              Tributyltin Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO01491   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation Tributyltin induces the drug-metabolizing activity of DME CYP19A1 [113]
                              YM-511 Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO00805   XEOTIC Info Gene Form Protein
                                 Classification Investigative Agent
                                 DME Modulation YM-511 inhibits the drug-metabolizing activity of DME CYP19A1 (IC50 = 0.00012 microM) [67]
      Other Chemical Compound(s) or Element(s)
                  Chemical Compound Click to Show/Hide the Full List of Xenobiotics:        2 Xenobiotics
                              Aniline Click to Show/Hide the Detail Inhibition
                                 XEOTIC ID XEO02228   XEOTIC Info Gene Form Protein
                                 Classification Chemical Compound
                                 DME Modulation Aniline inhibits the drug-metabolizing activity of DME CYP19A1 [21]
                              Naphthalene Click to Show/Hide the Detail Induction
                                 XEOTIC ID XEO00764   XEOTIC Info Gene Form Protein
                                 Classification Chemical Compound
                                 DME Modulation Naphthalene induces the drug-metabolizing activity of DME CYP19A1 [114]
References
1 Modulation of steroidogenic gene expression and hormone synthesis in H295R cells exposed to PCP and TCP. Toxicology. 2011 Apr 11;282(3):146-53.
2 A benzimidazole fungicide, benomyl, and its metabolite, carbendazim, induce aromatase activity in a human ovarian granulose-like tumor cell line (KGN). Endocrinology. 2004 Apr;145(4):1860-9.
3 Cell-based high-throughput screening for aromatase inhibitors in the Tox21 10K library. Toxicol Sci. 2015 Oct;147(2):446-57.
4 Modulation of aromatase activity and mRNA by various selected pesticides in the human choriocarcinoma JEG-3 cell line. Toxicology. 2006 Nov 10;228(1):98-108.
5 Comparative assessment of the inhibition of recombinant human CYP19 (aromatase) by azoles used in agriculture and as drugs for humans. Endocr Res. 2004 Aug;30(3):387-94.
6 Induction and inhibition of aromatase (CYP19) activity by various classes of pesticides in H295R human adrenocortical carcinoma cells. Toxicol Appl Pharmacol. 2002 Jul 1;182(1):44-54.
7 Epigallocatechin-3-gallate (EGCG) protects against chromate-induced toxicity in vitro. Toxicol Appl Pharmacol. 2012 Jan 15;258(2):166-75.
8 Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
9 CYP4A11 is repressed by retinoic acid in human liver cells. FEBS Lett. 2006 Jun 12;580(14):3361-7.
10 From transient transcriptome responses to disturbed neurodevelopment: role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol. 2014 Jul;88(7):1451-68.
11 Stem cell transcriptome responses and corresponding biomarkers that indicate the transition from adaptive responses to cytotoxicity. Chem Res Toxicol. 2017 Apr 17;30(4):905-922.
12 Cytotoxic effects and aromatase inhibition by xenobiotic endocrine disrupters alone and in combination. Toxicol Appl Pharmacol. 2007 Jul 15;222(2):129-40.
13 Organophosphorus pesticides enhance the genotoxicity of benzo(a)pyrene by modulating its metabolism. Mutat Res. 2009 Dec 1;671(1-2):84-92.
14 Disruption of the hormonal network and the enantioselectivity of bifenthrin in trophoblast: maternal-fetal health risk of chiral pesticides. Environ Sci Technol. 2014 Jul 15;48(14):8109-16.
15 Screening of selected pesticides for inhibition of CYP19 aromatase activity in vitro. Toxicol In Vitro. 2000 Jun;14(3):227-34.
16 Molecular mechanisms of discrotophos-induced toxicity in HepG2 cells: The role of CSA in oxidative stress. Food Chem Toxicol. 2017 May;103:253-260.
17 The use of a unique co-culture model of fetoplacental steroidogenesis as a screening tool for endocrine disruptors: The effects of neonicotinoids on aromatase activity and hormone production. Toxicol Appl Pharmacol. 2017 Oct 1;332:15-24.
18 Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Hepatology. 1999 Aug;30(2):476-84.
19 Induction of the UDP-glucuronosyltransferase 1A1 during the perinatal period can cause neurodevelopmental toxicity. Mol Pharmacol. 2016 Sep;90(3):265-74.
20 Using expression profiling to understand the effects of chronic cadmium exposure on MCF-7 breast cancer cells. PLoS One. 2013 Dec 20;8(12):e84646.
21 Novel sulfonanilide analogues suppress aromatase expression and activity in breast cancer cells independent of COX-2 inhibition. J Med Chem. 2006 Feb 23;49(4):1413-9.
22 An investigation of the endocrine disrupting potential of enniatin B using in vitro bioassays. Toxicol Lett. 2015 Mar 4;233(2):84-94.
23 Differentiation of human placental BeWo cells by the environmental contaminant benzo(a)pyrene. Chem Biol Interact. 2014 Mar 5;210:1-11.
24 Aflatoxin B1--a potential endocrine disruptor--up-regulates CYP19A1 in JEG-3 cells. Toxicol Lett. 2011 May 10;202(3):161-7.
25 Effects of brominated flame retardants and brominated dioxins on steroidogenesis in H295R human adrenocortical carcinoma cell line. Environ Toxicol Chem. 2007 Apr;26(4):764-72.
26 Differential effects of glyphosate and roundup on human placental cells and aromatase. Environ Health Perspect. 2005 Jun;113(6):716-20.
27 Time- and dose-dependent effects of roundup on human embryonic and placental cells. Arch Environ Contam Toxicol. 2007 Jul;53(1):126-33.
28 High fat diet-induced hepatic 18-carbon fatty acids accumulation up-regulates CYP2A5/CYP2A6 via NF-E2-related factor 2. Front Pharmacol. 2017 May 15;8:233.
29 A comparison of two human cell lines and two rat gonadal cell primary cultures as in vitro screening tools for aromatase modulation. Toxicol In Vitro. 2012 Feb;26(1):107-18.
30 Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci. 2009 Dec;100(12):2402-10.
31 Comparative toxicity, oxidative stress and endocrine disruption potential of plasticizers in JEG-3 human placental cells. Toxicol In Vitro. 2017 Feb;38:41-48.
32 Effects of currently used pesticides in assays for estrogenicity, androgenicity, and aromatase activity in vitro. Toxicol Appl Pharmacol. 2002 Feb 15;179(1):1-12.
33 Di-(2-ethylhexyl)-phthalate induces apoptosis via the PPARgama/PTEN/AKT pathway in differentiated human embryonic stem cells. Food Chem Toxicol. 2019 Sep;131:110552.
34 An in vitro investigation of endocrine disrupting effects of trichothecenes deoxynivalenol (DON), T-2 and HT-2 toxins. Toxicol Lett. 2012 Nov 15;214(3):268-78.
35 Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells. Toxicol Sci. 2004 Nov;82(1):70-9.
36 Endoplasmic reticulum stress impairs insulin signaling through mitochondrial damage in SH-SY5Y cells. Neurosignals. 2012;20(4):265-80.
37 New 7,8-benzoflavanones as potent aromatase inhibitors: synthesis and biological evaluation. Bioorg Med Chem. 2008 Feb 1;16(3):1474-80.
38 Design, synthesis and evaluation of 4-imidazolylflavans as new leads for aromatase inhibition. Bioorg Med Chem Lett. 2002 Oct 21;12(20):2859-61.
39 Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
40 Inhibition of aromatase activity by flavonoids. Arch Pharm Res. 1999 Jun;22(3):309-12.
41 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
42 Ginkgo biloba extract EGb 761-mediated inhibition of aromatase for the treatment of hormone-dependent breast cancer. Food Chem Toxicol. 2016 Jan;87:157-65.
43 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
44 Trialkyltin compounds bind retinoid X receptor to alter human placental endocrine functions. Mol Endocrinol. 2005 Oct;19(10):2502-16.
45 Modulation of steroidogenic gene expression and hormone production of H295R cells by pharmaceuticals and other environmentally active compounds. Toxicol Appl Pharmacol. 2007 Dec 1;225(2):142-53.
46 Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
47 Regulation of aromatase and 5alpha-reductase by 25-hydroxyvitamin D(3), 1alpha,25-dihydroxyvitamin D(3), dexamethasone and progesterone in prostate cancer cells. J Steroid Biochem Mol Biol. 2005 Feb;94(1-3):151-7.
48 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
49 Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer. J Steroid Biochem Mol Biol. 2005 May;95(1-5):129-36.
50 Effects of selective serotonin reuptake inhibitors on three sex steroids in two versions of the aromatase enzyme inhibition assay and in the H295R cell assay. Toxicol In Vitro. 2015 Oct;29(7):1729-35.
51 High copper levels in follicular fluid affect follicle development in polycystic ovary syndrome patients: population-based and in vitro studies. Toxicol Appl Pharmacol. 2019 Feb 15;365:101-111.
52 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
53 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
54 Conversion of dehydroepiandrosterone to downstream steroid hormones in macrophages. J Endocrinol. 2000 Feb;164(2):161-9.
55 The modulation of aromatase and estrogen receptor alpha in cultured human dermal papilla cells by dexamethasone: a novel mechanism for selective action of estrogen via estrogen receptor beta? J Invest Dermatol. 2006 Sep;126(9):2010-8.
56 Dienogest inhibits aromatase and cyclooxygenase-2 expression and prostaglandin E?production in human endometriotic stromal cells in spheroid culture. Fertil Steril. 2012 Feb;97(2):477-82.
57 Prostaglandin E2 down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity-breast cancer connection. J Biol Chem. 2019 Jan 4;294(1):361-371.
58 Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer Res. 2004 Dec 15;10(24):8163-9.
59 A positive feedback pathway of estrogen biosynthesis in breast cancer cells is contained by resveratrol. Toxicology. 2008 Jun 27;248(2-3):130-5.
60 Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer. Eur J Med Chem. 2015 Nov 13;105:1-38.
61 Inhibition of human aromatase complex (CYP19) by antiepileptic drugs. Toxicol In Vitro. 2008 Feb;22(1):146-53.
62 Evaluation of synthesized coumarin derivatives on aromatase inhibitory activity. Bioorg Med Chem Lett. 2017 Jun 15;27(12):2645-2649.
63 Modulation of aromatase expression in human breast tissue. J Steroid Biochem Mol Biol. 2001 Dec;79(1-5):35-40.
64 Selective oestrogen receptor modulators, aromatase inhibitors and the female breast. Curr Opin Obstet Gynecol. 2005 Aug;17(4):429-34.
65 Synthesis and evaluation of heteroaryl-substituted dihydronaphthalenes and indenes: potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem. 2006 Apr 6;49(7):2222-31.
66 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
67 Discovery and development of the aryl O-sulfamate pharmacophore for oncology and women's health. J Med Chem. 2015 Oct 8;58(19):7634-58.
68 Differential effects of antiepileptic drugs on steroidogenesis in a human in vitro cell model. Acta Neurol Scand Suppl. 2009;(189):14-21.
69 Aromatase activity modulation by lindane and bisphenol-A in human placental JEG-3 and transfected kidney E293 cells. Toxicol In Vitro. 2003 Aug;17(4):413-22.
70 Complex role of zinc in methamphetamine toxicity in vitro. Neuroscience. 2010 Nov 24;171(1):31-9.
71 Bioactivation of sitaxentan in liver microsomes, hepatocytes, and expressed human P450s with characterization of the glutathione conjugate by liquid chromatography tandem mass spectrometry. Chem Res Toxicol. 2013 Jun 17;26(6):926-36.
72 An integrated metabonomics and transcriptomics approach to understanding metabolic pathway disturbance induced by perfluorooctanoic acid. J Pharm Biomed Anal. 2013 Dec;86:56-64.
73 Use of high-throughput enzyme-based assay with xenobiotic metabolic capability to evaluate the inhibition of acetylcholinesterase activity by organophosphorous pesticides. Toxicol In Vitro. 2019 Apr;56:93-100.
74 Changes in trophoblasts gene expression in response to perchlorate exposition. Toxicol In Vitro. 2018 Aug;50:328-335.
75 Sulforaphane, erucin, and iberin up-regulate thioredoxin reductase 1 expression in human MCF-7 cells. J Agric Food Chem. 2005 Mar 9;53(5):1417-21.
76 Is there a case for P-450 inhibitors in cancer treatment? J Med Chem. 1989 Oct;32(10):2231-9.
77 Induction of cytochromes P450 1A1 and 1A2 by tanshinones in human HepG2 hepatoma cell line. Toxicol Appl Pharmacol. 2011 Apr 1;252(1):18-27.
78 Comparison of cellular and transcriptomic effects between electronic cigarette vapor and cigarette smoke in human bronchial epithelial cells. Toxicol In Vitro. 2017 Dec;45(Pt 3):417-425.
79 Organotin exposure stimulates steroidogenesis in H295R Cell via cAMP pathway. Ecotoxicol Environ Saf. 2018 Jul 30;156:148-153.
80 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
81 Bisphenol A downregulates CYP19 transcription in JEG-3 cells. Toxicol Lett. 2009 Sep 28;189(3):248-52.
82 AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. Toxicol Sci. 2014 May;139(1):198-209.
83 Screening of herbal constituents for aromatase inhibitory activity. Bioorg Med Chem. 2008 Sep 15;16(18):8466-70.
84 Assessment of estrogenic potential of diethyl phthalate in female reproductive system involving both genomic and non-genomic actions. Reprod Toxicol. 2014 Nov;49:12-26.
85 Recent progress in the discovery of next generation inhibitors of aromatase from the structure-function perspective. J Med Chem. 2016 Jun 9;59(11):5131-48.
86 Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78.
87 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
88 Functional gene expression profile underlying methotrexate-induced senescence in human colon cancer cells. Tumour Biol. 2011 Oct;32(5):965-76.
89 Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res. 2009 Jul 1;69(13):5415-23.
90 Optimization of the aromatase inhibitory activities of pyridylthiazole analogues of resveratrol. Bioorg Med Chem. 2012 Apr 1;20(7):2427-34.
91 Optimizing thiadiazole analogues of resveratrol versus three chemopreventive targets. Bioorg Med Chem. 2012 Jan 1;20(1):510-20.
92 Bisphenol A affects estradiol metabolism by targeting CYP1A1 and CYP19A1 in human placental JEG-3 cells. Toxicol In Vitro. 2019 Dec;61:104615.
93 The effect of valproate and levetiracetam on steroidogenesis in forskolin-stimulated H295R cells. Epilepsia. 2010 Nov;51(11):2280-8.
94 Bakuchiol suppresses oestrogen/testosterone-induced Benign Prostatic Hyperplasia development through up-regulation of epithelial estrogen receptor beta and down-regulation of stromal aromatase. Toxicol Appl Pharmacol. 2019 Oct 15;381:114637.
95 Low-dose bisphenol A activates the ERK signaling pathway and attenuates steroidogenic gene expression in human placental cells. Biol Reprod. 2018 Feb 1;98(2):250-258.
96 Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells. Toxicol Lett. 2018 Jul;291:77-85.
97 Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols. ChemMedChem. 2007 Dec;2(12):1750-62.
98 Novel sulfonanilide analogs decrease aromatase activity in breast cancer cells: synthesis, biological evaluation, and ligand-based pharmacophore identification. J Med Chem. 2008 Mar 13;51(5):1126-35.
99 Perfluorooctane sulfonate (PFOS) affects hormone receptor activity, steroidogenesis, and expression of endocrine-related genes in vitro and in vivo. Environ Toxicol Chem. 2013 Feb;32(2):353-60.
100 2-Chloro-s-triazine herbicides induce aromatase (CYP19) activity in H295R human adrenocortical carcinoma cells: a novel mechanism for estrogenicity? Toxicol Sci. 2000 Mar;54(1):121-7.
101 Effects of chloro-s-triazine herbicides and metabolites on aromatase activity in various human cell lines and on vitellogenin production in male carp hepatocytes. Environ Health Perspect. 2001 Oct;109(10):1027-31.
102 Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol Appl Pharmacol. 2009 Nov 1;240(3):355-66.
103 Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
104 Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun. 2000 May 19;271(3):710-3.
105 Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. Chem Biol Interact. 2013 Mar 25;203(1):226-30.
106 Geraniol protects against the protein and oxidative stress induced by rotenone in an in Vitro model of Parkinson's disease. Neurochem Res. 2018 Oct;43(10):1947-1962.
107 Synthesis and biological evaluation of selective aromatase expression regulators in breast cancer cells. J Med Chem. 2007 Apr 5;50(7):1635-44.
108 Identification of AhR-regulated genes involved in PAH-induced immunotoxicity using a highly-sensitive DNA chip, 3D-Gene human immunity and metabolic syndrome 9k. Toxicol In Vitro. 2010 Feb;24(1):85-91.
109 Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue. J Steroid Biochem Mol Biol. 2005 May;95(1-5):17-23.
110 Effects of single and repeated in vitro exposure of three forms of parabens, methyl-, butyl- and propylparabens on the proliferation and estradiol secretion in MCF-7 and MCF-10A cells. Pharmacol Rep. 2013;65(2):484-93.
111 Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells. Toxicology. 2012 Aug 16;298(1-3):14-23.
112 The effects of o,p'-DDD on human adrenal steroid synthesis. Nihon Naibunpi Gakkai Zasshi. 1984 Jul 20;60(7):852-71.
113 Effects of retinoic acid on N-glycosylation and mRNA stability of the liver/bone/kidney alkaline phosphatase in neuronal cells. J Cell Physiol. 2000 Jan;182(1):50-61.
114 Selective COX-2 inhibitors modulate cellular senescence in human dermal fibroblasts in a catalytic activity-independent manner. Mech Ageing Dev. 2008 Dec;129(12):706-13.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.